TC OT 39, also known as "compound 39", is a non-peptide partial agonist of the oxytocin and vasopressin V2 receptors (Ki = 147 nM and >1,000 nM, respectively) and antagonist of the vasopressin V1A receptor (Ki = 330 nM). The EC50Tooltip half-maximal effective concentration values of the drug were 33 nM at the oxytocin receptor and 850 nM at the vasopressin V2 receptor. TC OT 39 was first described in the scientific literature by Gary R. W. Pitt and colleagues in 2004. The drug was the first small-molecule oxytocin receptor agonist to be described, though it was the lead optimized compound of a described series of compounds. Subsequently, improved analogues like WAY-267,464 (2010), LIT-001 (2018), and LIT-002 (2026) were described.
See also Oxytocin receptor agonist WAY-267,464 LIT-001 LIT-002 KNX-100
References


